Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zykadia
Pharma
Pfizer's Lorbrena makes play for earlier lung cancer use
If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.
Carly Helfand
Aug 5, 2020 12:00pm
Takeda eyes Alunbrig earlier use with Xalkori head-to-head data
Nov 22, 2019 10:00pm
Big Pharmas slash cancer drug prices again for Chinese insurance
Oct 10, 2018 11:32am
Takeda's Alunbrig bests Xalkori in untreated ALK+ lung cancer
Jul 25, 2018 12:56pm
Pfizer's Xalkori picks up two new FDA 'breakthrough' tags
May 29, 2018 12:15pm
16 blockbuster nods in 2018's China: report
Jan 5, 2018 9:59am
